BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27:423-431. [PMID: 16341948 DOI: 10.1007/s11096-005-1319-7] [Cited by in Crossref: 129] [Cited by in F6Publishing: 116] [Article Influence: 8.1] [Reference Citation Analysis]
Number Citing Articles
1 Sossau D, Kofler L, Eigentler T. Type 1 diabetes mellitus caused by treatment with low-dose interferon-α in a melanoma patient. Melanoma Research 2017;27:516-8. [DOI: 10.1097/cmr.0000000000000381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
2 Driessen C, Noppen C, Boonen G, Drewe J. Complete hematological and major molecular response through treatment with low-dose Interferon alpha 2a in high-risk polycythemia vera patient: a case report. Clin Case Rep 2021;9:e04903. [PMID: 34631086 DOI: 10.1002/ccr3.4903] [Reference Citation Analysis]
3 Rubio-Ponce A, Hidalgo A, Ballesteros I. How to bridle a neutrophil. Curr Opin Immunol 2021;68:41-7. [PMID: 33038850 DOI: 10.1016/j.coi.2020.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bridwell R, Long B, Gottlieb M. Neurologic complications of COVID-19. Am J Emerg Med 2020;38:1549.e3-7. [PMID: 32425321 DOI: 10.1016/j.ajem.2020.05.024] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 32.5] [Reference Citation Analysis]
5 Paul F, Pellegrini S, Uzé G. IFNA2: The prototypic human alpha interferon. Gene 2015;567:132-7. [PMID: 25982860 DOI: 10.1016/j.gene.2015.04.087] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
6 Oishi A, Miyamoto K, Kashii S, Yoshimura N. Abducens palsy and Sjogren's syndrome induced by pegylated interferon therapy. Br J Ophthalmol 2007;91:843-4. [PMID: 17510485 DOI: 10.1136/bjo.2006.110494] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
7 Tseng SH, Cheng MA, Farmer E, Ferrall L, Kung YJ, Lam B, Lim L, Wu TC, Hung CF. Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity. J Immunother Cancer 2022;10:e004342. [PMID: 35459734 DOI: 10.1136/jitc-2021-004342] [Reference Citation Analysis]
8 Hui RW, Mak LY, Seto WK, Yuen MF. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: A spotlight on drugs at phase II clinical trials. Expert Opin Emerg Drugs 2022. [PMID: 35511483 DOI: 10.1080/14728214.2022.2074977] [Reference Citation Analysis]
9 Vázquez-Vandyck M, Roman S, Vázquez J, Huacuja L, Khalsa G, Troyo-Sanromán R, Panduro A. Effect of Breathwalk on body composition, metabolic and mood state in chronic hepatitis C patients with insulin resistance syndrome. World J Gastroenterol 2007; 13(46): 6213-6218 [PMID: 18069762 DOI: 10.3748/wjg.v13.i46.6213] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
10 Ying W, Kanameni S, Chang CA, Nair V, Safe S, Bazer FW, Zhou B. Interferon tau alleviates obesity-induced adipose tissue inflammation and insulin resistance by regulating macrophage polarization. PLoS One 2014;9:e98835. [PMID: 24905566 DOI: 10.1371/journal.pone.0098835] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
11 Wester NE, Hutten EM, Krikke C, Pol RA. Intra-abdominal localisation of a buschke-lowenstein tumour: case presentation and review of the literature. Case Rep Transplant 2013;2013:187682. [PMID: 24159412 DOI: 10.1155/2013/187682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Feng Q, Langereis MA, Olagnier D, Chiang C, van de Winkel R, van Essen P, Zoll J, Hiscott J, van Kuppeveld FJ. Coxsackievirus cloverleaf RNA containing a 5' triphosphate triggers an antiviral response via RIG-I activation. PLoS One 2014;9:e95927. [PMID: 24759703 DOI: 10.1371/journal.pone.0095927] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
13 Uricoli B, Birnbaum LA, Do P, Kelvin JM, Jain J, Costanza E, Chyong A, Porter CC, Rafiq S, Dreaden EC. Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. Adv Healthc Mater 2021;10:e2002214. [PMID: 33690997 DOI: 10.1002/adhm.202002214] [Reference Citation Analysis]
14 Abdel-Wahab N, Alshawa A, Suarez-Almazor ME. Adverse Events in Cancer Immunotherapy. Adv Exp Med Biol 2017;995:155-74. [PMID: 28321817 DOI: 10.1007/978-3-319-53156-4_8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
15 Maticic M, Poljak M, Lunder T, Rener-sitar K, Stojanovic L. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. J Eur Acad Dermatol Venerol 2008;22:779-88. [DOI: 10.1111/j.1468-3083.2008.02676.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
16 Glitscher M, Hildt E. Endosomal Cholesterol in Viral Infections - A Common Denominator? Front Physiol 2021;12:750544. [PMID: 34858206 DOI: 10.3389/fphys.2021.750544] [Reference Citation Analysis]
17 Hakim FA, Singh S, Pandit A, Alegria JR, Camoriano J, Stanton ML, Mookadam F. Interferon-α and pericardial injury: a case report and literature review. Heart Asia 2014;6:48-53. [PMID: 27326167 DOI: 10.1136/heartasia-2013-010488] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Yin H, Chen N, Guo R, Wang H, Li W, Wang G, Cui J, Jin H, Hu JF. Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells. Sci Rep 2015;5:16975. [PMID: 26584517 DOI: 10.1038/srep16975] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
19 King CA, Wegman AD, Endy TP. Mobilization and Activation of the Innate Immune Response to Dengue Virus. Front Cell Infect Microbiol 2020;10:574417. [PMID: 33224897 DOI: 10.3389/fcimb.2020.574417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Sagnelli C, Sagnelli E, Russo A, Pisaturo M, Occhiello L, Coppola N. HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges. Life (Basel) 2021;11:169. [PMID: 33671730 DOI: 10.3390/life11020169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chalise JP, Pallotta MT, Narendra SC, Carlsson B, Iacono A, Namale J, Boon L, Grohmann U, Magnusson M. IDO1 and TGF-β Mediate Protective Effects of IFN-α in Antigen-Induced Arthritis. J Immunol 2016;197:3142-51. [PMID: 27647832 DOI: 10.4049/jimmunol.1502125] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
22 Zhao G, Wu H, Jiang K, Rui G, Zhu Z, Qiu C, Guo M, Deng G. IFN-τ inhibits S. aureus-induced inflammation by suppressing the activation of NF-κB and MAPKs in RAW 264.7 cells and mice with pneumonia. International Immunopharmacology 2016;35:332-40. [DOI: 10.1016/j.intimp.2016.02.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
23 Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer. 2015;4:51-69. [PMID: 26020029 DOI: 10.1159/000367728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
24 Liu D, Zeng X, Ding Z, Lv F, Mehta JL, Wang X. Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. Front Pharmacol 2021;12:699949. [PMID: 34512335 DOI: 10.3389/fphar.2021.699949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Basar O, Dailey F, Dailey E, Tahan V, Daglilar E. Interferon-Induced Crohn's Disease: An Unusual Side Effect of Interferon Therapy in a Patient With Chronic Hepatitis C Virus Infection. Cureus 2021;13:e15568. [PMID: 34277190 DOI: 10.7759/cureus.15568] [Reference Citation Analysis]
26 [DOI: 10.1101/2020.10.15.340612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Kamiyama R, Yoshimi R, Takeno M, Iribe Y, Tsukahara T, Kishimoto D, Kunishita Y, Sugiyama Y, Tsuchida N, Nakano H, Minegishi K, Tamura M, Asami Y, Kirino Y, Ishigatsubo Y, Ozato K, Nakajima H. Dysfunction of TRIM21 in interferon signature of systemic lupus erythematosus. Mod Rheumatol 2018;28:993-1003. [PMID: 29385873 DOI: 10.1080/14397595.2018.1436028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
28 Rauw J, Ahmed S, Petrella T. Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma. Med Oncol 2012;29:1304-7. [DOI: 10.1007/s12032-011-9935-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
29 Schlecker C, Ultsch A, Geisslinger G, Lötsch J. The pharmacogenetic background of hepatitis C treatment. Mutat Res. 2012;Epub ahead of print. [PMID: 22409946 DOI: 10.1016/j.mrrev.2012.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
30 Raciti L, Calabrò RS. Neurological complications of COVID-19: from pathophysiology to rehabilitation. An overview. Acta Biomed 2021;92:e2021317. [PMID: 34487099 DOI: 10.23750/abm.v92i4.10620] [Reference Citation Analysis]
31 Jarry A, Malard F, Bou-Hanna C, Meurette G, Mohty M, Mosnier JF, Laboisse CL, Bossard C. Interferon-Alpha Promotes Th1 Response and Epithelial Apoptosis via Inflammasome Activation in Human Intestinal Mucosa. Cell Mol Gastroenterol Hepatol 2017;3:72-81. [PMID: 28174758 DOI: 10.1016/j.jcmgh.2016.09.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
32 Ren C, Kumar S, Chanda D, Chen J, Mountz JD, Ponnazhagan S. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells. 2008;26:2332-2338. [PMID: 18617688 DOI: 10.1634/stemcells.2008-0084] [Cited by in Crossref: 123] [Cited by in F6Publishing: 120] [Article Influence: 8.8] [Reference Citation Analysis]
33 Flaum N, Valle JW, Mansoor W, Mcnamara MG. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. Future Oncology 2016;12:2561-78. [DOI: 10.2217/fon.16.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
34 Trochopoulos AGX, Zaharieva MM, Marinova MH, Yoncheva K, Tibi IP, Berger MR, Konstantinov SM. Antineoplastic effect of a novel nanosized curcumin on cutaneous T cell lymphoma. Oncol Lett 2020;20:304. [PMID: 33093913 DOI: 10.3892/ol.2020.12167] [Reference Citation Analysis]
35 Berke JM, Dehertogh P, Vergauwen K, Van Damme E, Mostmans W, Vandyck K, Pauwels F. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus. Antimicrob Agents Chemother. 2017;61. [PMID: 28584155 DOI: 10.1128/aac.00560-17] [Cited by in Crossref: 61] [Cited by in F6Publishing: 28] [Article Influence: 12.2] [Reference Citation Analysis]
36 Vinod BS, Maliekal TT, Anto RJ. Phytochemicals as chemosensitizers: from molecular mechanism to clinical significance. Antioxid Redox Signal 2013;18:1307-48. [PMID: 22871022 DOI: 10.1089/ars.2012.4573] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 8.3] [Reference Citation Analysis]
37 Shie FS, Chen YH, Chen CH, Ho IK. Neuroimmune pharmacology of neurodegenerative and mental diseases. J Neuroimmune Pharmacol 2011;6:28-40. [PMID: 20820930 DOI: 10.1007/s11481-010-9241-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
38 Da BL, Heller T, Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep (Oxf) 2019;7:231-45. [PMID: 32477569 DOI: 10.1093/gastro/goz023] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Ugarte S, Mehrmal S, Knopf K. Chemotherapy with paclitaxel for recalcitrant molluscum contagiosum in an HIV-infected patient. BMJ Case Rep 2021;14:e240776. [PMID: 34112632 DOI: 10.1136/bcr-2020-240776] [Reference Citation Analysis]
40 Freeman SC, Satish M, Walters RW. Comorbidity burden on receipt of adjuvant immunotherapy and survival in patients with stage III melanoma: an analysis of the National Cancer Database. Int J Dermatol 2020;59:1381-90. [PMID: 32592609 DOI: 10.1111/ijd.15019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Makunda N, Vallabhaneni S, Lefebvre B, Fradley MG. Cardiotoxicity of Systemic Melanoma Treatments. Curr Treat Options Oncol 2022. [PMID: 35192138 DOI: 10.1007/s11864-021-00924-2] [Reference Citation Analysis]
42 Jobard E, Blanc E, Négrier S, Escudier B, Gravis G, Chevreau C, Elena-Herrmann B, Trédan O. A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma. Br J Cancer 2015;113:1148-57. [PMID: 26372698 DOI: 10.1038/bjc.2015.322] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
43 Fischer B, Reimer J, Firestone M, Kalousek K, Rehm J, Heathcote J. Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions. Eur J Gastroenterol Hepatol 2006;18:1039-42. [PMID: 16957507 DOI: 10.1097/01.meg.0000236869.93527.b9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
44 Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opinion on Drug Metabolism & Toxicology 2008;4:1537-49. [DOI: 10.1517/17425250802525496] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 4.3] [Reference Citation Analysis]
45 Wang X, Lei J, Li Z, Yan L. Potential Effects of Coronaviruses on the Liver: An Update. Front Med (Lausanne) 2021;8:651658. [PMID: 34646834 DOI: 10.3389/fmed.2021.651658] [Reference Citation Analysis]
46 Schmidlin H, Dontje W, Groot F, Ligthart SJ, Colantonio AD, Oud ME, Schilder-Tol EJ, Spaargaren M, Spits H, Uittenbogaart CH, Blom B. Stimulated plasmacytoid dendritic cells impair human T-cell development. Blood 2006;108:3792-800. [PMID: 16917011 DOI: 10.1182/blood-2006-02-004978] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
47 DeKelver RC, Lewin B, Weng S, Yan M, Biggs J, Zhang DE. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development. Leuk Lymphoma 2014;55:884-91. [PMID: 23772668 DOI: 10.3109/10428194.2013.815351] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
48 Shan B, Wang JY, Wang X, Fu JJ, Li L, Pan XC, Li JJ, Tang XT. VDR rs7975232/ApaI genetic variation predicts sustained HBsAg loss in HBeAg-positive chronic hepatitis B patients treated with pegylated interferon. J Med Virol 2019;91:765-74. [PMID: 30516836 DOI: 10.1002/jmv.25373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Robinson-Mosher A, Chen JH, Way J, Silver PA. Designing cell-targeted therapeutic proteins reveals the interplay between domain connectivity and cell binding. Biophys J 2014;107:2456-66. [PMID: 25418314 DOI: 10.1016/j.bpj.2014.10.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
50 Yoon SY, Won JH. The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms. Blood Res 2021;56:S44-50. [PMID: 33935035 DOI: 10.5045/br.2021.2020334] [Reference Citation Analysis]
51 Patel D, Chan D, Cehic G, Pavlakis N, Price TJ. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert Rev Endocrinol Metab 2016;11:311-27. [PMID: 30058926 DOI: 10.1080/17446651.2016.1199952] [Reference Citation Analysis]
52 Biggioggero M, Gabbriellini L, Meroni PL. Type I interferon therapy and its role in autoimmunity. Autoimmunity 2010;43:248-54. [DOI: 10.3109/08916930903510971] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
53 Huang J, Zhang X, Tong J, Du J, Duan R, Yang L, Moore JH, Tao C, Chen Y. Comparing drug safety of hepatitis C therapies using post-market data. BMC Med Inform Decis Mak 2019;19:147. [PMID: 31391106 DOI: 10.1186/s12911-019-0860-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
54 Keshtkar-Jahromi M, Martins KAO, Cardile AP, Reisler RB, Christopher GW, Bavari S. Treatment-focused Ebola trials, supportive care and future of filovirus care. Expert Rev Anti Infect Ther 2018;16:67-76. [PMID: 29210303 DOI: 10.1080/14787210.2018.1413937] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
55 Smorodin E, Sergeyev B, Kurtenkov O, Kuznetsova T, Geller J. IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment. Dis Markers 2018;2018:4639805. [PMID: 30627223 DOI: 10.1155/2018/4639805] [Reference Citation Analysis]
56 Wang X, Huang H, Su C, Zhong Q, Wu G. Cilostazol ameliorates high free fatty acid (FFA)-induced activation of NLRP3 inflammasome in human vascular endothelial cells. Artif Cells Nanomed Biotechnol 2019;47:3704-10. [PMID: 31514535 DOI: 10.1080/21691401.2019.1665058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
57 Eriksen KW, Søndergaard H, Woetmann A, Krejsgaard T, Skak K, Geisler C, Wasik MA, Ødum N. The combination of IL-21 and IFN-α boosts STAT3 activation, cytotoxicity and experimental tumor therapy. Molecular Immunology 2009;46:812-20. [DOI: 10.1016/j.molimm.2008.09.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
58 Wu H, Zhao G, Jiang K, Chen X, Rui G, Qiu C, Guo M, Deng G. IFN-τ Alleviates Lipopolysaccharide-Induced Inflammation by Suppressing NF-κB and MAPKs Pathway Activation in Mice. Inflammation 2016;39:1141-50. [PMID: 27052630 DOI: 10.1007/s10753-016-0348-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
59 Zhao G, Wu H, Jiang K, Chen X, Wang X, Qiu C, Guo M, Deng G. The Anti-Inflammatory Effects of Interferon Tau by Suppressing NF-κB/MMP9 in Macrophages Stimulated with Staphylococcus aureus. J Interferon Cytokine Res 2016;36:516-24. [PMID: 27142785 DOI: 10.1089/jir.2015.0170] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
60 Pires IS, Hammond PT, Irvine DJ. Engineering Strategies for Immunomodulatory Cytokine Therapies - Challenges and Clinical Progress. Adv Ther (Weinh) 2021;4:2100035. [PMID: 34734110 DOI: 10.1002/adtp.202100035] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Rumi E, Cazzola M. How I treat essential thrombocythemia. Blood 2016;128:2403-14. [DOI: 10.1182/blood-2016-05-643346] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
62 Jinato T, Chuaypen N, Poomipak W, Praianantathavorn K, Makkoch J, Kiatbumrung R, Jampoka K, Tangkijvanich P, Payungporn S. Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment. Exp Biol Med (Maywood) 2016;241:1803-10. [PMID: 27190255 DOI: 10.1177/1535370216647184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
63 Ceaglio N, Gugliotta A, Tardivo MB, Cravero D, Etcheverrigaray M, Kratje R, Oggero M. Improvement of in vitro stability and pharmacokinetics of hIFN-α by fusing the carboxyl-terminal peptide of hCG β-subunit. J Biotechnol 2016;221:13-24. [PMID: 26806490 DOI: 10.1016/j.jbiotec.2016.01.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
64 Paludan SR. Innate Antiviral Defenses Independent of Inducible IFNα/β Production. Trends Immunol 2016;37:588-96. [PMID: 27345728 DOI: 10.1016/j.it.2016.06.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
65 Woelk CH, Frost SD, Richman DD, Higley PE, Kosakovsky Pond SL. Evolution of the interferon alpha gene family in eutherian mammals. Gene 2007;397:38-50. [PMID: 17512142 DOI: 10.1016/j.gene.2007.03.018] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 3.3] [Reference Citation Analysis]
66 Emran TB, Iyori M, Ono Y, Amelia F, Yusuf Y, Islam A, Alam A, Tamura M, Ogawa R, Matsuoka H, Yamamoto DS, Yoshida S. Baculovirus-Induced Fast-Acting Innate Immunity Kills Liver-Stage Plasmodium. J Immunol 2018;201:2441-51. [PMID: 30209187 DOI: 10.4049/jimmunol.1800908] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
67 Borcherding N, Jethava Y, Vikas P. Repurposing Anti-Cancer Drugs for COVID-19 Treatment. Drug Des Devel Ther 2020;14:5045-58. [PMID: 33239864 DOI: 10.2147/DDDT.S282252] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
68 Leitner WW, Bergmann-Leitner ES, Hwang LN, Restifo NP. Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 2006;24:5110-8. [PMID: 16725231 DOI: 10.1016/j.vaccine.2006.04.059] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
69 Casselman P, Cassiman C, Casteels I, Schauwvlieghe PP. Insights into multiple sclerosis-associated uveitis: a scoping review. Acta Ophthalmol 2020. [PMID: 33326162 DOI: 10.1111/aos.14697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Schiller M, Tsianakas A, Sterry W, Dummer R, Hinke A, Nashan D, Stadler R. Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2017;31:1841-7. [PMID: 28557110 DOI: 10.1111/jdv.14366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
71 Lightcap ES, Yu P, Grossman S, Song K, Khattar M, Xega K, He X, Gavin JM, Imaichi H, Garnsey JJ, Koenig E, Zhang H, Lu Z, Shah P, Fu Y, Milhollen MA, Hatton BA, Riceberg J, Shinde V, Li C, Minissale J, Yang X, England D, Klinghoffer RA, Langston S, Galvin K, Shapiro G, Pulukuri SM, Fuchs SY, Huszar D. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models. Sci Transl Med 2021;13:eaba7791. [PMID: 34524860 DOI: 10.1126/scitranslmed.aba7791] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Vázquez-Vandyck M, Roman S, Vázquez JL, Huacuja L, Khalsa G, Troyo-Sanromán R, Panduro A. Effect of Breathwalk on body composition, metabolic and mood state in chronic hepatitis C patients with insulin resistance syndrome. World J Gastroenterol. 2007;13:6213-6218. [PMID: 18069762 DOI: 10.3748/wjg.13.6213] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
73 Descotes J, Vial T. Flu-Like Syndrome and Cytokines. In: House RV, Descotes J, editors. Cytokines in Human Health. Totowa: Humana Press; 2007. pp. 193-204. [DOI: 10.1007/978-1-59745-350-9_10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
74 Lassner D, Siegismund CS, Kühl U, Rohde M, Stroux A, Escher F, Schultheiss HP. CCR5del32 genotype in human enteroviral cardiomyopathy leads to spontaneous virus clearance and improved outcome compared to wildtype CCR5. J Transl Med 2018;16:249. [PMID: 30180856 DOI: 10.1186/s12967-018-1610-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
75 Bezak B, Lehrke H, Elvin J, Gay L, Schembri-wismayer D, Viozzi C. Comprehensive Genomic Profiling of Central Giant Cell Lesions Identifies Clinically Relevant Genomic Alterations. Journal of Oral and Maxillofacial Surgery 2017;75:955-61. [DOI: 10.1016/j.joms.2016.10.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
76 Eggermont LJ, Hammink R, Blank KG, Rowan AE, Tel J, Figdor CG. Cytokine-Functionalized Synthetic Dendritic Cells for T Cell Targeted Immunotherapies. Adv Therap 2018;1:1800021. [DOI: 10.1002/adtp.201800021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
77 McHugh KJ. Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19. Bioeng Transl Med 2020;5:e10163. [PMID: 32440566 DOI: 10.1002/btm2.10163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
78 Lopušná K, Benkóczka T, Lupták J, Matúšková R, Lukáčiková Ľ, Ovečková I, Režuchová I. Murine gammaherpesvirus targets type I IFN receptor but not type III IFN receptor early in infection. Cytokine 2016;83:158-70. [PMID: 27152708 DOI: 10.1016/j.cyto.2016.04.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
79 Mora B, Passamonti F. Developments in diagnosis and treatment of essential thrombocythemia. Expert Rev Hematol 2019;12:159-71. [PMID: 30793984 DOI: 10.1080/17474086.2019.1585239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
80 van de Wetering D, van Wengen A, Savage ND, van de Vosse E, van Dissel JT. IFN-α cannot substitute lack of IFN-γ responsiveness in cells of an IFN-γR1 deficient patient. Clin Immunol 2011;138:282-90. [PMID: 21216674 DOI: 10.1016/j.clim.2010.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
81 Tovey MG, Lallemand C. Safety, Tolerability, and Immunogenicity of Interferons. Pharmaceuticals (Basel) 2010;3:1162-86. [PMID: 27713294 DOI: 10.3390/ph3041162] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
82 Goh ZY, Ren EC, Ko HL. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B. World J Gastroenterol 2021; 27(14): 1369-1391 [PMID: 33911462 DOI: 10.3748/wjg.v27.i14.1369] [Reference Citation Analysis]
83 Ferreira‐da‐silva R, Ribeiro‐vaz I, Morato M, Junqueira Polónia J. A comprehensive review of adverse events to drugs used in COVID‐19 patients: Recent clinical evidence. Eur J Clin Investigation. [DOI: 10.1111/eci.13763] [Reference Citation Analysis]
84 Büssow K, Themann P, Luu S, Pentrowski P, Harting C, Majewski M, Vollmer V, Köster M, Grashoff M, Zawatzky R, Van den Heuvel J, Kröger A, Böldicke T. ER intrabody-mediated inhibition of interferon α secretion by mouse macrophages and dendritic cells. PLoS One 2019;14:e0215062. [PMID: 30990863 DOI: 10.1371/journal.pone.0215062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
85 Martins LB, Monteze NM, Calarge C, Ferreira AVM, Teixeira AL. Pathways linking obesity to neuropsychiatric disorders. Nutrition 2019;66:16-21. [DOI: 10.1016/j.nut.2019.03.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
86 . Pharmacological activation of STING blocks SARS-CoV-2 infection. Sci Immunol 2021;6:eabi9007. [PMID: 34010142 DOI: 10.1126/sciimmunol.abi9007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
87 Tsai HY, Chueh LL, Lin CN, Su BL. Clinicopathological findings and disease staging of feline infectious peritonitis: 51 cases from 2003 to 2009 in Taiwan. J Feline Med Surg 2011;13:74-80. [PMID: 21216644 DOI: 10.1016/j.jfms.2010.09.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
88 Anbarasu A, Ramaiah S, Livingstone P. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality? Hum Vaccin Immunother 2020;16:2217-8. [PMID: 32501133 DOI: 10.1080/21645515.2020.1773141] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
89 Healy FM, Dahal LN, Jones JRE, Floisand Y, Woolley JF. Recent Progress in Interferon Therapy for Myeloid Malignancies. Front Oncol 2021;11:769628. [PMID: 34778087 DOI: 10.3389/fonc.2021.769628] [Reference Citation Analysis]
90 Osaki LH, Mills JC. A Perfect Match: Explant and Organoid Systems Help Study Cytokines in Sickness and Health. Cell Mol Gastroenterol Hepatol 2017;3:4-5. [PMID: 28174752 DOI: 10.1016/j.jcmgh.2016.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
91 Kasumba DM, Grandvaux N. Therapeutic Targeting of RIG-I and MDA5 Might Not Lead to the Same Rome. Trends Pharmacol Sci 2019;40:116-27. [PMID: 30606502 DOI: 10.1016/j.tips.2018.12.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
92 Rand U, Kupke SY, Shkarlet H, Hein MD, Hirsch T, Marichal-Gallardo P, Cicin-Sain L, Reichl U, Bruder D. Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. Cells 2021;10:1756. [PMID: 34359926 DOI: 10.3390/cells10071756] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Ichimata S, Kobayashi M, Honda K, Shibata S, Matsumoto A, Kanno H. Acquired amegakaryocytic thrombocytopenia previously diagnosed as idiopathic thrombocytopenic purpura in a patient with hepatitis C virus infection. World J Gastroenterol 2017; 23(35): 6540-6545 [PMID: 29085203 DOI: 10.3748/wjg.v23.i35.6540] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
94 Law AD, Dong Hwan Kim D, Lipton JH. Pregnancy: part of life in chronic myelogenous leukemia. Leuk Lymphoma 2017;58:280-7. [PMID: 27389567 DOI: 10.1080/10428194.2016.1201571] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
95 Cooley-Andrade O, Jothidas A, Goh WX, Connor DE, Parsi K. Low-concentration detergent sclerosants stimulate white blood cells and release proinflammatory and proangiogenic cytokines in vitro. J Vasc Surg Venous Lymphat Disord 2014;2:433-40. [PMID: 26993550 DOI: 10.1016/j.jvsv.2014.02.005] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
96 Sharma J, Bonfield CM, Singhal A, Hukin J, Steinbok P. Intracystic interferon-α treatment leads to neurotoxicity in craniopharyngioma: case report. J Neurosurg Pediatr 2015;16:301-4. [PMID: 26023721 DOI: 10.3171/2015.2.PEDS14656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
97 Shahid K, Khalife M, Dabney R, Phan AT. Immunotherapy and targeted therapy-the new roadmap in cancer treatment. Ann Transl Med 2019;7:595. [PMID: 31807576 DOI: 10.21037/atm.2019.05.58] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
98 Ben-Zuk N, Dechtman ID, Henn I, Weiss L, Afriat A, Krasner E, Gal Y. Potential Prophylactic Treatments for COVID-19. Viruses 2021;13:1292. [PMID: 34372498 DOI: 10.3390/v13071292] [Reference Citation Analysis]
99 Mccormack PL. Pazopanib: A Review of Its Use in the Management of Advanced Renal Cell Carcinoma. Drugs 2014;74:1111-25. [DOI: 10.1007/s40265-014-0243-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
100 Palma-Ocampo HK, Flores-Alonso JC, Vallejo-Ruiz V, Reyes-Leyva J, Flores-Mendoza L, Herrera-Camacho I, Rosas-Murrieta NH, Santos-López G. Interferon lambda inhibits dengue virus replication in epithelial cells. Virol J 2015;12:150. [PMID: 26411318 DOI: 10.1186/s12985-015-0383-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
101 Kavanagh S, Nee A, Lipton JH. Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia. Expert Opin Emerg Drugs 2018;23:51-62. [PMID: 29480034 DOI: 10.1080/14728214.2018.1445717] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
102 Drake GJ, Haycock J, Dastjerdi A, Davies H, Lopez FJ. Use of immunostimulants in the successful treatment of a clinical EEHV1A infection in an Asian elephant ( Elephas maximus ). Vet rec case rep 2020;8. [DOI: 10.1136/vetreccr-2020-001158] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
103 Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT. Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors. Curr Opin Organ Transplant 2019;24:351-7. [PMID: 31090648 DOI: 10.1097/MOT.0000000000000651] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Shimazui T, Kojima T, Yoshikawa K, Ami Y, Oikawa T, Uchida K, Akaza H. Low expression of microphthalmia-associated transcription factor, a potential molecular target for interferon-alpha susceptibility, is associated with metastasis in renal cell carcinoma. Cancer Sci 2009;100:1714-8. [PMID: 19496784 DOI: 10.1111/j.1349-7006.2009.01216.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
105 Hafidh RR, Abdulamir AS, Abu Bakar F, Sekawi Z, Jahansheri F, Jalilian FA. Novel antiviral activity of mung bean sprouts against respiratory syncytial virus and herpes simplex virus -1: an in vitro study on virally infected Vero and MRC-5 cell lines. BMC Complement Altern Med 2015;15:179. [PMID: 26062546 DOI: 10.1186/s12906-015-0688-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
106 Nguyen HA, Cooke GS, Day JN, Flower B, Phuong LT, Hung TM, Dung NT, Khoa DB, Hung LM, Kestelyn E, Thwaites GE, Chau NVV, Turner HC; SEARCH Investigators. The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. Wellcome Open Res 2019;4:129. [PMID: 32734002 DOI: 10.12688/wellcomeopenres.15408.2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf 2011;2:113-28. [PMID: 25083207 DOI: 10.1177/2042098611406318] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
108 Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet 2017;389:612-20. [PMID: 28069279 DOI: 10.1016/S0140-6736(16)31403-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 29] [Article Influence: 11.4] [Reference Citation Analysis]
109 Shimazui T, Ami Y, Yoshikawa K, Uchida K, Kojima T, Oikawa T, Nakamura K, Honda N, Hinotsu S, Miyazaki J, Kunita N, Akaza H. Prediction of in vitro response to interferon-? in renal cell carcinoma cell lines. Cancer Science 2007;98:529-34. [DOI: 10.1111/j.1349-7006.2007.00421.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
110 Nihal M, Ahsan H, Siddiqui IA, Mukhtar H, Ahmad N, Wood GS. (-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma. Cell Cycle 2009;8:2057-63. [PMID: 19502799 DOI: 10.4161/cc.8.13.8862] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
111 Adán A, Mesquida M, Llorenç V. Biologic drugs in noninfectious uveitis: an update. Expert Review of Ophthalmology 2014;8:501-16. [DOI: 10.1586/17469899.2013.843453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 2022. [PMID: 34997230 DOI: 10.1038/s41571-021-00588-9] [Reference Citation Analysis]
113 Koh C, Da BL, Glenn JS. HBV/HDV Coinfection: A Challenge for Therapeutics. Clin Liver Dis 2019;23:557-72. [PMID: 31266627 DOI: 10.1016/j.cld.2019.04.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
114 Ianevski A, Yao R, Zusinaite E, Lello LS, Wang S, Jo E, Yang J, Ravlo E, Wang W, Lysvand H, Løseth K, Oksenych V, Tenson T, Windisch MP, Poranen MM, Nieminen AI, Nordbø SA, Fenstad MH, Grødeland G, Aukrust P, Trøseid M, Kantele A, Lastauskienė E, Vitkauskienė A, Legrand N, Merits A, Bjørås M, Kainov DE. Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections. Viruses 2021;13:2489. [PMID: 34960758 DOI: 10.3390/v13122489] [Reference Citation Analysis]
115 Stein BL, Moliterno AR, Tiu RV. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Ann Hematol 2014;93:1965-76. [DOI: 10.1007/s00277-014-2205-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
116 Stefan KL, Kim MV, Iwasaki A, Kasper DL. Commensal Microbiota Modulation of Natural Resistance to Virus Infection. Cell 2020;183:1312-1324.e10. [PMID: 33212011 DOI: 10.1016/j.cell.2020.10.047] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 13.5] [Reference Citation Analysis]
117 Saghazadeh A, Rezaei N. Implications of Toll-like receptors in Ebola infection. Expert Opin Ther Targets 2017;21:415-25. [PMID: 28281905 DOI: 10.1080/14728222.2017.1299128] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
118 Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212-223. [PMID: 21386812 DOI: 10.1038/nrgastro.2011.21] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 8.5] [Reference Citation Analysis]
119 Janiga J, Kentley J, Nabhan C, Abdulla F. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome. Leuk Lymphoma 2018;59:562-77. [PMID: 29308723 DOI: 10.1080/10428194.2017.1347650] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
120 Rathnasinghe R, Salvatore M, Zheng H, Jangra S, Kehrer T, Mena I, Schotsaert M, Muster T, Palese P, García-Sastre A. Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1. Sci Rep 2021;11:22164. [PMID: 34773048 DOI: 10.1038/s41598-021-01780-8] [Reference Citation Analysis]
121 Hong E, Dobrovolskaia MA. Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics. Advanced Drug Delivery Reviews 2019;141:3-22. [DOI: 10.1016/j.addr.2018.01.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
122 Contet A, Caussanel V, Beck A, Lowe P. [Immunotoxins and immunocytokines]. Med Sci (Paris) 2019;35:1054-61. [PMID: 31903917 DOI: 10.1051/medsci/2019205] [Reference Citation Analysis]
123 Soday L, Potts M, Hunter LM, Ravenhill BJ, Houghton JW, Williamson JC, Antrobus R, Wills MR, Matheson NJ, Weekes MP. Comparative Cell Surface Proteomic Analysis of the Primary Human T Cell and Monocyte Responses to Type I Interferon. Front Immunol 2021;12:600056. [PMID: 33628210 DOI: 10.3389/fimmu.2021.600056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Hayn M, Hirschenberger M, Koepke L, Nchioua R, Straub JH, Klute S, Hunszinger V, Zech F, Prelli Bozzo C, Aftab W, Christensen MH, Conzelmann C, Müller JA, Srinivasachar Badarinarayan S, Stürzel CM, Forne I, Stenger S, Conzelmann KK, Münch J, Schmidt FI, Sauter D, Imhof A, Kirchhoff F, Sparrer KMJ. Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities. Cell Rep 2021;35:109126. [PMID: 33974846 DOI: 10.1016/j.celrep.2021.109126] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
125 Sauviller S, Vergauwen K, Jaensch S, Gustin E, Peeters D, Vermeulen P, Wuyts D, Vandyck K, Pauwels F, Berke JM. Development of a cellular high-content, immunofluorescent HBV core assay to identify novel capsid assembly modulators that induce the formation of aberrant HBV core structures. J Virol Methods 2021;293:114150. [PMID: 33839187 DOI: 10.1016/j.jviromet.2021.114150] [Reference Citation Analysis]
126 Kitahara Y, Kawane K, Nagata S. Interferon-induced TRAIL-independent cell death in DNase II-/- embryos. Eur J Immunol 2010;40:2590-8. [PMID: 20706988 DOI: 10.1002/eji.201040604] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
127 Chartrand K, Lebel MÈ, Tarrab E, Savard P, Leclerc D, Lamarre A. Efficacy of a Virus-Like Nanoparticle As Treatment for a Chronic Viral Infection Is Hindered by IRAK1 Regulation and Antibody Interference. Front Immunol 2017;8:1885. [PMID: 29354118 DOI: 10.3389/fimmu.2017.01885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
128 Quiroga AD, Comanzo CG, Heit Barbini FJ, Lucci A, Vera MC, Lorenzetti F, Ferretti AC, Ceballos MP, Alvarez ML, Carrillo MC. IFN-α-2b treatment protects against diet-induced obesity and alleviates non-alcoholic fatty liver disease in mice. Toxicol Appl Pharmacol 2019;379:114650. [PMID: 31299271 DOI: 10.1016/j.taap.2019.114650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
129 Nada S, Abdel-salam O, Sleem A. Cannabis and Hepatic Injury. Handbook of Cannabis and Related Pathologies. Elsevier; 2017. pp. 505-16. [DOI: 10.1016/b978-0-12-800756-3.00062-4] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
130 Lei V, Handfield C, Kwock JT, Kirchner SJ, Lee MJ, Coates M, Wang K, Han Q, Wang Z, Powers JG, Wolfe S, Corcoran DL, Fanelli B, Dadlani M, Ji RR, Zhang JY, MacLeod AS. Skin Injury Activates A Rapid TRPV1-dependent Antiviral Protein Response. J Invest Dermatol 2022:S0022-202X(21)02637-3. [PMID: 35007556 DOI: 10.1016/j.jid.2021.11.041] [Reference Citation Analysis]
131 Furutani Y, Toguchi M, Shiozaki-Sato Y, Qin XY, Ebisui E, Higuchi S, Sudoh M, Suzuki H, Takahashi N, Watashi K, Wakita T, Kakeya H, Kojima S. An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes. PLoS One 2019;14:e0216139. [PMID: 31188831 DOI: 10.1371/journal.pone.0216139] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
132 Asif B, Koh C. Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials. Expert Opin Investig Drugs 2021;:1-16. [PMID: 34482769 DOI: 10.1080/13543784.2021.1977795] [Reference Citation Analysis]
133 Davis J, Umeh U, Saba R. Treatment of SARS-CoV-2 (COVID-19): A safety perspective. World J Pharmacol 2021; 10(1): 1-32 [DOI: 10.5497/wjp.v10.i1.1] [Reference Citation Analysis]